Piramal Imaging said that WVU Healthcare in West Virginia is the first center in the U.S. to perform commercial scans using its Neuraceq radiopharmaceutical.
Neuraceq is indicated for PET imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline.
Neuraceq received marketing authorization in the European Union and the U.S. earlier this year and became available for commercial use on August 1.
